Tuesday, July 7, 2026

Depo-Provera Settlement Process Anchors Week’s 673-Filing Surge

This week’s docket activity produced 673 new filings across 40 active tort and mass-action categories, but the strongest procedural shift came from the Depo-Provera litigation (MDL 3140), where 84 new cases arrived as Judge M. Casey Rodgers continued steering a June 2026 eligible-plaintiff resolution process. McSweeney Langevin LLC led the Depo-Provera filings with 23 complaints, while Murphy Law Firm and Schlichter Bogard LLP added eight each. The settlement posture is narrower than a full-docket resolution: Pretrial Order No. 30A reflects a global agreement between Plaintiffs’ Lead Counsel and Pfizer-side defendants for eligible MDL plaintiffs, while preserving unresolved claims and leaving the Rule 702 hearing on calendar for July 27, 2026. Raw volume still belonged to Suboxone (MDL 3092), where Nigh Goldenberg Raso Vaughn PLLC filed 106 of 109 new cases as Judge J. Philip Calabrese moved the bellwether process toward a 50-case Core Discovery Pool, July 2 selection order, and depositions beginning July 13. Uber Passenger Sexual Assault (MDL 3084) added 95 filings, led by 60 from Cutter Law PC, while Social Media Addiction (MDL 3047) added 75 actions, including 53 from Wright & Schulte LLC, as Judge Yvonne Gonzalez Rogers kept the state-attorney-general public-law track headed toward August openings after denying Meta summary judgment on key claims.

Ethylene Oxide Studies Sharpen Low-Dose Cancer-Risk Debate

Two new toxicology studies published July 1 and July 2, 2026, add fresh molecular-dosimetry evidence to the litigation and regulatory fight over ethylene oxide sterilization emissions. In one study, researchers exposed mice to EtO by inhalation and found statistically significant increases in the hemoglobin adduct N-(2-hydroxyethyl)-L-valine even at 0.05 ppm, with linear increases at lower concentrations and nonlinear toxicokinetics at higher doses. A companion DNA-adduct study found dose-response evidence across lung, liver, bone marrow, and mammary tissue, including linear low-dose behavior for the more abundant N7-(2-hydroxyethyl)guanine adduct and higher-dose detection of the mutagenic O6-HE-dG adduct. For plaintiffs alleging cancer risks from medical-sterilization facilities, the papers provide current biomarker and mechanism-of-action material that could sharpen expert fights over low-level exposure, dose reconstruction, and whether facility-neighbor claims can bridge the gap between ambient emissions and individual cancer causation.

Paraquat Judge Orders Opt-Out Plaintiffs Into Settlement Review

In June 2026, U.S. District Judge Nancy J. Rosenstengel escalated pressure on plaintiffs in the Paraquat products liability MDL (MDL 3004) who are declining Syngenta settlement offers, directing nonparticipating claimants to meet individually with Special Master Randi S. Ellis to confirm they understand the offer and the consequences of rejecting it. The June 12 case-management order followed earlier orders targeting high opt-out firms for limited discovery, and a July 6 status-report deadline shifted attention to which plaintiffs had accepted, rejected, or remained undecided on the settlement framework. The process targets a growing opt-out bloc in litigation alleging paraquat exposure causes Parkinson’s disease, with selected plaintiffs also facing discovery into their use histories and claim support. For plaintiffs, the process raises the stakes of rejecting confidential settlement terms; for defendants, it creates a procedural mechanism to test whether unresolved claims can survive renewed scrutiny after years of causation fights.